Dataset Information

Germline mutations in RAD51D confer susceptibility to ovarian cancer.

ABSTRACT: Recently, RAD51C mutations were identified in families with breast and ovarian cancer. This observation prompted us to investigate the role of RAD51D in cancer susceptibility. We identified eight inactivating RAD51D mutations in unrelated individuals from 911 breast-ovarian cancer families compared with one inactivating mutation identified in 1,060 controls (P = 0.01). The association found here was principally with ovarian cancer, with three mutations identified in the 59 pedigrees with three or more individuals with ovarian cancer (P = 0.0005). The relative risk of ovarian cancer for RAD51D mutation carriers was estimated to be 6.30 (95% CI 2.86-13.85, P = 4.8 × 10(-6)). By contrast, we estimated the relative risk of breast cancer to be 1.32 (95% CI 0.59-2.96, P = 0.50). These data indicate that RAD51D mutation testing may have clinical utility in individuals with ovarian cancer and their families. Moreover, we show that cells deficient in RAD51D are sensitive to treatment with a PARP inhibitor, suggesting a possible therapeutic approach for cancers arising in RAD51D mutation carriers.

SUBMITTER: Loveday C

PROVIDER: S-EPMC4845885 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Germline mutations in RAD51D confer susceptibility to ovarian cancer.

Loveday Chey C Turnbull Clare C Ramsay Emma E Hughes Deborah D Ruark Elise E Frankum Jessica R JR Bowden Georgina G Kalmyrzaev Bolot B Warren-Perry Margaret M Snape Katie K Adlard Julian W JW Barwell Julian J Berg Jonathan J Brady Angela F AF Brewer Carole C Brice Glen G Chapman Cyril C Cook Jackie J Davidson Rosemarie R Donaldson Alan A Douglas Fiona F Greenhalgh Lynn L Henderson Alex A Izatt Louise L Kumar Ajith A Lalloo Fiona F Miedzybrodzka Zosia Z Morrison Patrick J PJ Paterson Joan J Porteous Mary M Rogers Mark T MT Shanley Susan S Walker Lisa L Eccles Diana D Evans D Gareth DG Renwick Anthony A Seal Sheila S Lord Christopher J CJ Ashworth Alan A Reis-Filho Jorge S JS Antoniou Antonis C AC Rahman Nazneen N

Nature genetics 20110807 9

Recently, RAD51C mutations were identified in families with breast and ovarian cancer. This observation prompted us to investigate the role of RAD51D in cancer susceptibility. We identified eight inactivating RAD51D mutations in unrelated individuals from 911 breast-ovarian cancer families compared with one inactivating mutation identified in 1,060 controls (P = 0.01). The association found here was principally with ovarian cancer, with three mutations identified in the 59 pedigrees with three o ...[more]

PMID: 21822267

Similar Datasets

Project description:BACKGROUND:It is unclear whether germline breast cancer susceptibility gene mutations affect breast cancer related outcomes. We wanted to evaluate mutation patterns in 20 breast cancer susceptibility genes and correlate the mutations with clinical characteristics to determine the effects of these germline mutations on breast cancer prognosis. METHODS:The study cohort included 480 ethnic Chinese individuals in Taiwan with at least one of the six clinical risk factors for hereditary breast cancer: family history of breast or ovarian cancer, young age of onset for breast cancer, bilateral breast cancer, triple negative breast cancer, both breast and ovarian cancer, and male breast cancer. PCR-enriched amplicon-sequencing on a next generation sequencing platform was used to determine the germline DNA sequences of all exons and exon-flanking regions of the 20 genes. Protein-truncating variants were identified as pathogenic. RESULTS:We detected a 13.5% carrier rate of pathogenic germline mutations, with BRCA2 being the most prevalent and the non-BRCA genes accounting for 38.5% of the mutation carriers. BRCA mutation carriers were more likely to be diagnosed of breast cancer with lymph node involvement (66.7% vs 42.6%; P?=?0.011), and had significantly worse breast cancer specific outcomes. The 5-year disease-free survival was 73.3% for BRCA mutation carriers and 91.1% for non-carriers (hazard ratio for recurrence or death 2.42, 95% CI 1.29-4.53; P?=?0.013). After adjusting for clinical prognostic factors, BRCA mutation remained an independent poor prognostic factor for cancer recurrence or death (adjusted hazard ratio 3.04, 95% CI 1.40-6.58; P?=?0.005). Non-BRCA gene mutation carriers did not exhibit any significant difference in cancer characteristics or outcomes compared to those without detected mutations. Among the risk factors for hereditary breast cancer, the odds of detecting a germline mutation increased significantly with having bilateral breast cancer (adjusted odds ratio 3.27, 95% CI 1.64-6.51; P?=?0.0008) or having more than one risk factor (odds ratio 2.07, 95% CI 1.22-3.51; P?=?0.007). CONCLUSIONS:Without prior knowledge of the mutation status, BRCA mutation carriers had more advanced breast cancer on initial diagnosis and worse cancer-related outcomes. Optimal approach to breast cancer treatment for BRCA mutation carriers warrants further investigation.

Dataset Information

Germline mutations in RAD51D confer susceptibility to ovarian cancer.

Publications

Germline mutations in RAD51D confer susceptibility to ovarian cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure